Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release

Respiratory Research

Sabina-Marija Janciauskiene²  Ulla Westin¹  Camilla Hollander¹  Izabela Nita² 

[1] Department of Otolaryngology and Head and Neck Surgery, Lund University, University Hospital Malmö, 20502 Malmö, Sweden;Department of Medicine, Lund University, University Hospital Malmö, 20502 Malmö, Sweden

关键词: endotoxin;    inflammation;    neutrophils;    monocytes;    Prolastin;    α1- antitrypsin;   

Others  :  1227335
DOI  :  10.1186/1465-9921-6-12

 received in 2004-11-05, accepted in 2005-01-31,  发布年份 2005

【 摘 要 】

Background

α1-antitrypsin (AAT) serves primarily as an inhibitor of the elastin degrading proteases, neutrophil elastase and proteinase 3. There is ample clinical evidence that inherited severe AAT deficiency predisposes to chronic obstructive pulmonary disease. Augmentation therapy for AAT deficiency has been available for many years, but to date no sufficient data exist to demonstrate its efficacy. There is increasing evidence that AAT is able to exert effects other than protease inhibition. We investigated whether Prolastin, a preparation of purified pooled human AAT used for augmentation therapy, exhibits anti-bacterial effects.

Methods

Human monocytes and neutrophils were isolated from buffy coats or whole peripheral blood by the Ficoll-Hypaque procedure. Cells were stimulated with lipopolysaccharide (LPS) or zymosan, either alone or in combination with Prolastin, native AAT or polymerised AAT for 18 h, and analysed to determine the release of TNFα, IL-1β and IL-8. At 2-week intervals, seven subjects were submitted to a nasal challenge with sterile saline, LPS (25 μg) and LPS-Prolastin combination. The concentration of IL-8 was analysed in nasal lavages performed before, and 2, 6 and 24 h after the challenge.

Results

In vitro, Prolastin showed a concentration-dependent (0.5 to 16 mg/ml) inhibition of endotoxin-stimulated TNFα and IL-1β release from monocytes and IL-8 release from neutrophils. At 8 and 16 mg/ml the inhibitory effects of Prolastin appeared to be maximal for neutrophil IL-8 release (5.3-fold, p < 0.001 compared to zymosan treated cells) and monocyte TNFα and IL-1β release (10.7- and 7.3-fold, p < 0.001, respectively, compared to LPS treated cells). Furthermore, Prolastin (2.5 mg per nostril) significantly inhibited nasal IL-8 release in response to pure LPS challenge.

Conclusion

Our data demonstrate for the first time that Prolastin inhibits bacterial endotoxin-induced pro-inflammatory responses in vitro and in vivo, and provide scientific bases to explore new Prolastin-based therapies for individuals with inherited AAT deficiency, but also for other clinical conditions.

【 授权许可】

   
2005 Nita et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 3.

【 参考文献 】

• [1]Potempa J, Korzus E, Travis J: The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994, 269:15957-15960.
• [2]Brantly ML: Alpha-1-antitrypsin genotypes and phenotypes. In Alpha-1-antitrypsin. Edited by Crystal RG. New York, Marcel Dekker; 1996:45-59.
• [3]Kalsheker N, Morley S, Morgan K: Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin. Biochem Soc Trans 2002, 30:93-98.
• [4]Olsen GN, Harris JO, Castle JR, Waldman RH, Karmgard HJ: Alpha-1-antitrypsin content in the serum, alveolar macrophages, and alveolar lavage fluid of smoking and nonsmoking normal subjects. J Clin Invest 1975, 55:427-430.
• [5]Travis J, Shieh BH, Potempa J: The functional role of acute phase plasma proteinase inhibitors. Tokai J Exp Clin Med 1988, 13:313-320.
• [6]Crystal RG: The alpha 1-antitrypsin gene and its deficiency states. Trends Genet 1989, 5:411-417.
• [7]Hutchison DC: Natural history of alpha-1-protease inhibitor deficiency. Am J Med 1988, 84:3-12.
• [8]Needham M, Stockley RA: Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004, 59:441-445.
• [9]Lomas DA, Mahadeva R: Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002, 110:1585-1590.
• [10]Luisetti M, Seersholm N: Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004, 59:164-169.
• [11]Carrell RW, Lomas DA: Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med 2002, 346:45-53.
• [12]Eriksson S: Alpha 1-antitrypsin deficiency. J Hepatol 1999, 30 Suppl 1:34-39.
• [13]Wiedemann HP, Stoller JK: Lung disease due to alpha 1-antitrypsin deficiency. Curr Opin Pulm Med 1996, 2:155-160.
• [14]Stockley RA: Alpha-1-antitrypsin deficiency: what next? Thorax 2000, 55:614-618.
• [15]Sandford AJ, Weir TD, Spinelli JJ, Pare PD: Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1999, 20:287-291.
• [16]Talamo RC, Langley CE, Levine BW, Kazemi H: Genetic vs. quantitative analysis of serum alpha 1 -antitrypsin. N Engl J Med 1972, 287:1067-1069.
• [17]Guenter CA, Welch MH, Ferguson S, Henderson L, Hammarsten JF: Alpha-1-antitrypsin deficiency: heterozygosity, intermediate levels, and pulmonary disease. Chest 1971, 59:Suppl:16S+.
• [18]Sandford AJ, Silverman EK: Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax 2002, 57:736-741.
• [19]Chow CK: Cigarette smoking and oxidative damage in the lung. Ann N Y Acad Sci 1993, 686:289-298.
• [20]Laurell CB, Eriksson S: The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin dificiency. Scand J Clin Lab Invest 1963, 15:132-140.
• [21]Gross P, deTreville RT, Babyak MA, Kaschak M, Tolker EB: Experimental emphysema: effect of chronic nitrogen dioxide exposure and of papain on normal and pneumoconiotic lungs. Aspen Emphysema Conf 1967, 10:357-378.
• [22]Lieberman J, Winter B, Sastre A: Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986, 89:370-373.
• [23]Lieberman J: Intermediate antitrypsin deficiency. Am Rev Respir Dis 1990, 141:1078.
• [24]Gadek JE, Klein HG, Holland PV, Crystal RG: Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981, 68:1158-1165.
• [25]Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Crystal RG: Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987, 316:1055-1062.
• [26]Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG: Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989, 111:206-212.
• [27]Stoller JK, Aboussouan LS: alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding. Thorax 2004, 59:708-712.
• [28]Lieberman J: Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000, 118:1480-1485.
• [29]Stockley RA, Hill AT, Hill SL, Campbell EJ: Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency. Chest 2000, 117:291S-3S.
• [30]Dabbagh K, Laurent GJ, Shock A, Leoni P, Papakrivopoulou J, Chambers RC: Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol 2001, 186:73-81.
• [31]Jeannin P, Lecoanet-Henchoz S, Delneste Y, Gauchat JF, Bonnefoy JY: Alpha-1 antitrypsin up-regulates human B cell differentiation selectively into IgE- and IgG4- secreting cells. Eur J Immunol 1998, 28:1815-1822.
• [32]Ikari Y, Mulvihill E, Schwartz SM: alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells. J Biol Chem 2001, 276:11798-11803.
• [33]Daemen MA, Heemskerk VH, van't Veer C, Denecker G, Wolfs TG, Vandenabeele P, Buurman WA: Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000, 102:1420-1426.
• [34]Graziadei I, Gaggl S, Kaserbacher R, Braunsteiner H, Vogel W: The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 1994, 83:260-268.
• [35]Bucurenci N, Blake DR, Chidwick K, Winyard PG: Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett 1992, 300:21-24.
• [36]Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, Shapiro S, Wright JL: Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 2001, 81:1119-1131.
• [37]Jie Z, Cai Y, Yang W, Jin M, Zhu W, Zhu C: Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin Med J (Engl) 2003, 116:1678-1682.
• [38]Libert C, Van Molle W, Brouckaert P, Fiers W: alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996, 157:5126-5129.
• [39]Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T: Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 2004, 321:592-600.
• [40]Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
• [41]Wihl JA, Baumgarten CR, Petersson G: Contralateral differences among biomarkers determined by a modified nasal lavage technique after unilateral antigen challenge. Allergy 1995, 50:308-315.
• [42]Dickneite G, Leithauser B: Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999, 19:1566-1572.
• [43]Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E: Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001, 29:134-139.
• [44]Heumann D, Roger T: Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002, 323:59-72.
• [45]Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K: Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994, 56:559-564.
• [46]Anderson P, Phillips K, Stoecklin G, Kedersha N: Post-transcriptional regulation of proinflammatory proteins. J Leukoc Biol 2004, 76:42-47.
• [47]Chow MK, Devlin GL, Bottomley SP: Osmolytes as modulators of conformational changes in serpins. Biol Chem 2001, 382:1593-1599.
• [48]Huntington JA, Pannu NS, Hazes B, Read RJ, Lomas DA, Carrell RW: A 2.6 A structure of a serpin polymer and implications for conformational disease. J Mol Biol 1999, 293:449-455.
• [49]Schwartz DA, Thorne PS, Yagla SJ, Burmeister LF, Olenchock SA, Watt JL, Quinn TJ: The role of endotoxin in grain dust-induced lung disease. Am J Respir Crit Care Med 1995, 152:603-608.
• [50]Schwartz DA, Thorne PS, Jagielo PJ, White GE, Bleuer SA, Frees KL: Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. Am J Physiol 1994, 267:L609-17.
• [51]Peden DB, Tucker K, Murphy P, Newlin-Clapp L, Boehlecke B, Hazucha M, Bromberg P, Reed W: Eosinophil influx to the nasal airway after local, low-level LPS challenge in humans. J Allergy Clin Immunol 1999, 104:388-394.
• [52]Blaski CA, Watt JL, Quinn TJ, Thorne PS, Schwartz DA: Nasal lavage cellularity, grain dust, and airflow obstruction. Chest 1996, 109:1086-1092.
• [53]Sigsgaard T, Bonefeld-Jorgensen EC, Kjaergaard SK, Mamas S, Pedersen OF: Cytokine release from the nasal mucosa and whole blood after experimental exposures to organic dusts. Eur Respir J 2000, 16:140-145.
• [54]Danuser B, Rebsamen H, Weber C, Krueger H: Lipopolysaccharide-induced nasal cytokine response: a dose-response evaluation. Eur Arch Otorhinolaryngol 2000, 257:527-532.
• [55]Besancon-Watelet C, Bene MC, Montagne P, Faure GC, Jankowski R: Eosinophilia and cell activation mediators in nasal secretions. Laryngoscope 2002, 112:43-46.
• [56]Stoller JK: Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists. Respir Care 2003, 48:1022-1024.
• [57]Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA: Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000, 15:886-890.
• [58]Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J: A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160:1468-1472.
• [59]Cantin AM, Woods DE: Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med 1999, 160:1130-1135.
• [60]Stockley RA, Bayley DL, Unsal I, Dowson LJ: The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002, 165:1494-1498.